|Mr. David John Anderson MBA||Chief Financial Officer and Exec. VP||177.5k||N/A||68|
|Ms. Julie O'Neill MBA||Exec. VP of Global Operations||1.08M||N/A||61|
|Dr. Martin MacKay Ph.D.||Head of R&D and Exec. VP||1.15M||2.88M||60|
|Mr. Carsten Thiel Ph.D.||Chief Commercial Officer and Exec. VP||N/A||N/A||53|
|Dr. Ludwig N. Hantson Ph.D.||Chief Exec. Officer and Director||N/A||N/A||54|
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Alexion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 2; Compensation: 8.